Quick Answer
HERON THERAPEUTICS, INC. /DE/ reported Operating Income Loss of -$2.54 million for the year ending 2025.
- HERON THERAPEUTICS, INC. /DE/ showed an increase of +78.0% in Operating Income Loss from 2024 to 2025.
- This data is from HERON THERAPEUTICS, INC. /DE/'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), HERON THERAPEUTICS, INC. /DE/'s Operating Income Loss has grown by 75.2%.
- Historical annual values: Fiscal year 2025: -$2.54 million | Fiscal year 2024: -$11.53 million | Fiscal year 2023: -$110.62 million | Fiscal year 2022: -$174.66 million | Fiscal year 2021: -$217.83 million | Fiscal year 2020: -$228.16 million | Fiscal year 2019: -$210.69 million | Fiscal year 2018: -$183.94 million | Fiscal year 2017: -$194.56 million | Fiscal year 2016: -$170.92 million | Fiscal year 2015: -$96.93 million | Fiscal year 2014: -$74.56 million | Fiscal year 2013: -$54.46 million | Fiscal year 2012: -$23.83 million | Fiscal year 2011: -$11.06 million | Fiscal year 2010: -$9.93 million | Fiscal year 2009: -$10.24 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: